Use OCTA to detect the relationship between retinal vessels and atherosclerosis in patients with coronary heart disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035123

Enrollment

Unknown

Registered

2020-08-01

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary atherosclerotic heart disease

Interventions

case series:Nil

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. ACS patients undergoing selective coronary angiography; 2. The LDL - C 70 mg/dL or higher (1.8 or higher tendency/L); 3. Patients with carotid plaque shown by carotid artery color ultrasound or CAROTID artery MR; 4. Best corrected vision > 0.1; 5. Male or female aged >= 18 years.

Exclusion criteria

Exclusion criteria: 1. Clinical state instability (hemodynamic or electrodynamic instability); 2. Severe renal insufficiency to estimate the glomerular filtration rate.30 ml/min. 3. Active liver disease or liver dysfunction; 4. Known statin intolerance; 5. Patients who have received Evolocumab or other PCSK9 inhibitors; 6. Another research facility or drug study is currently under way; 7. Pregnant or lactating women; 8. Allergic or contraindicated to PCSK9 inhibitors; 9. Patients who have received intravitreal drug injection or laser therapy or fundus surgery; 10. Patients with other eye diseases that affect the ability to obtain clear images.

Design outcomes

Primary

Measure	Time frame
Retinal vessel density;Retinal vascular perfusion density;foveal avascular zone;coronary artery SYNTAX score;	—

Secondary

Measure	Time frame
FRS score;Grace score;creatinine;arbamide;glutamic oxalacetic transaminase;lutamic-pyruvic transaminase;glycosylated hemoglobin;NTPro-BNP;Ions in the blood;Troponin;C-Reactive Protein;platelet count;mean hemoglobin concentration;ymphocyte count;mean hemoglobin content;hemoglobin;RBC;monocyte count;neutrophil count;WBC count;superoxide dismutase;small and dense LDL cholesterol;lipoprotein A;Apolipoprotein E;Apolipoprotein B;apolipoprotein A;low-density lipoprotein;HIGH-density lipoprotein;total cholestero;Triglycerides;Coronary Artery Calcification Score;leaman score;CAS score;Gensini score;deep capillary density;ganglion cell layer thickness;nerve fiber layer thickness;choroidal capillary layer thickness;neovascularization perimeter;neovascularization area;visual acuity (best corrected visual acuity, BCVA);vitreous body;retina;neovascularization lesion perimeter;neovascularization lesion area;neovascularization lesion diameter;	—

Measure

Time frame

FRS score;Grace score;creatinine;arbamide;glutamic oxalacetic transaminase;lutamic-pyruvic transaminase;glycosylated hemoglobin;NTPro-BNP;Ions in the blood;Troponin;C-Reactive Protein;platelet count;mean hemoglobin concentration;ymphocyte count;mean hemoglobin content;hemoglobin;RBC;monocyte count;neutrophil count;WBC count;superoxide dismutase;small and dense LDL cholesterol;lipoprotein A;Apolipoprotein E;Apolipoprotein B;apolipoprotein A;low-density lipoprotein;HIGH-density lipoprotein;total cholestero;Triglycerides;Coronary Artery Calcification Score;leaman score;CAS score;Gensini score;deep capillary density;ganglion cell layer thickness;nerve fiber layer thickness;choroidal capillary layer thickness;neovascularization perimeter;neovascularization area;visual acuity (best corrected visual acuity, BCVA);vitreous body;retina;neovascularization lesion perimeter;neovascularization lesion area;neovascularization lesion diameter;

—

Countries

China

Contacts

Public ContactWei Yi

Shandong University

yi_wei@foxmail.com+86 18668956298

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026